3 results
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Primary Objective • To determine whether ITCA 650 is non-inferior either to empagliflozin or to glimepiride in reducing glycosylated hemoglobin A1c (HbA1c) or weight in patients with T2D following 65 weeks of treatment. The non-inferiority margins…
The primary objective is to determine the limited-efficacy of both the experimental systems in comparison to our previous cohort that was treated with the more traditional MCGR. Limited-efficacy will be determined in terms of maintenance of the…